The treatment of patients with neurotrophic keratitis, a rare disease of the eye that can lead to blindness, has evolved beyond treating symptoms to treatment that targets the root cause of the disease – nerve damage. Thus, early diagnosis is critical. The interprofessional faculty share their real-world experience as they discuss the etiology, diagnosis, staging, and treatment of patients with neurotrophic keratitis. In addition to an overview of symptomatic care and emerging treatments, the safety, efficacy, storage, and administration of cenegermin are explained in detail. Clinical and real-world questions are discussed, related to patient education, provided by the interprofessional, multidisciplinary team.
This activity is also available as a podcast: You may listen here
Course Credit:
1 AAPA Category I Hour
1 ACPE Contact Hour
1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour
0.25 Pharmacology Hours
Dates:
Opens: 2024-06-07
Closes: 2025-06-07
Target Audience:
This activity was developed for ophthalmologists, optometrists, and other clinicians who care for patients with corneal diseases.
This activity is supported by an educational grant from Dompé.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1 hour . Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 ANCC contact hour, including 0.25 pharmacology hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
Tim Drake, PharmD, MBA, BCPS (Medical Writer)No significant relationships to disclose.
Amber Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
No significant relationships to disclose.
Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Kenneth A. Beckman, MD, FACS
Comprehensive EyeCare of Central Ohio, Westerville, Ohio
The Ohio State University
Columbus, Ohio -
Stephanie L. Conway-Allen, PharmD, RPh
Associate Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Worcester, Massachusetts -
Preeya K. Gupta, MD
Managing Director, Triangle Eye Consultants
Raleigh, North Carolina
Adjunct Associate Professor of Ophthalmology,
Tulane University School of Medicine
New Orleans, Louisiana
Presenting Faculty
Downloads
Learning Objectives
- Distinguish the unique signs and symptoms associated with neurotrophic keratitis (NK)
- Explain the diagnostic criteria necessary for NK
- Employ evidence-based strategies for treating patients with NK
- Collaborate and communicate with other healthcare team members to provide patient education and ensure appropriate treatment and follow-up for NK
Faculty Disclosures
Kenneth A. Beckman, MD, FACS
Advisory Board: Ocular Science
Consultant: AbbVie, Alcon, Amgen, Bausch & Lomb, BioTissue, Dompé, Glint, Novaliq, Sinqi Pharma, Sun, Thea, Trukera, Versea, Yuyu Pharma
Ownership: Comprehensive EyeCare of Central Ohio
Stephanie L. Conway-Allen, PharmD, RPh
No relationships to disclose.Preeya K. Gupta, MD
Consultant: Azura, Alcon, Aldeyra, Allergan, Amring, Dompé, Expert Opinion, HanAll Biopharma, J&J Vision, Kala, New World Medical, Novartis, Ocular Science, Ocular Therapeutix, Orasis, Oyster Point, Sight Sciences, Spyglass, Surface Ophthalmics, Sun Pharmaceuticals, Tear Lab, Tear Clear, Tissue Tech, Inc., Trukera